|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal EPK)
| (51) | INT.CL. | A61K 31/395 | |
| A61P 7/06 | |||
| C07D 255/02 | |||
| A61K 45/06 | |||
| A61K 38/19 |
| (11) | Patento numeris | 2709991 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 12786739.8 |
| Europos patento paraiškos padavimo data | 2012-05-15 | |
| (97) | Europos patento paraiškos paskelbimo data | 2014-03-26 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2020-09-02 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (86) | Numeris | PCT/US2012/037970 |
| Data | 2012-05-15 |
| (87) | Numeris | WO 2012/158707 |
| Data | 2012-11-22 |
| (30) | Numeris | Data | Šalis |
| 201161486632 P | 2011-05-16 | US |
| (72) |
DALE, David, C., US
BRIDGER, Gary, J., US
HSU, Frank, J., US
|
| (73) |
University of Washington,
Center for Commercialization 4311 11th Avenue NE, Suite 500, Seattle, WA 98105,
US
Genzyme Corporation, 50 Binney Street, Cambridge, MA 02142, US |
| (54) | Use of cxcr4 antagonists for treating WHIM syndrome, myelokathexis, neutropenia and lymphocytopenia |
| Use of cxcr4 antagonists for treating WHIM syndrome, myelokathexis, neutropenia and lymphocytopenia |